Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank J Beurskens

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Molecular Immunology|June 3, 2015
C1q, antibodies and anti-C1q autoantibodiesFrank J Beurskens, Rosanne A van Schaarenburg, Leendert A Trouw
Critical Reviews in Immunology|June 19, 2014
Complement in antibody-based tumor therapyStefanie Derer, Frank J Beurskens, Thies Rosner, et al.
Seminars in Immunology|January 1, 2025
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approachesVitalijs Ovcinnikovs, Karin Dijkman, Gijs G Zom, et al.
Infection and Immunity|December 11, 2019
Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7Srinjoy Chakraborti, Sunita Gulati, Bo Zheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 22, 2024
Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen bindingNikolaus Frischauf, Jürgen Strasser, Ellen G F Borg, et al.
Small Science|July 16, 2025
A Kinetic Model of Antigen-Dependent IgG Oligomerization and Complement BindingJürgen Strasser, Nikolaus Frischauf, Lukas Schustereder, et al.
HLA|May 6, 2026
Blockade of Complement Cell Lysis and C3d Fixation by Patient HLA-A1 Antibodies: Towards a New Therapy for Prevention of Antibody-Mediated RejectionTineke Kardol-Hoefnagel, Dilara Akharman-Oztoprak, Els van der Meijden, et al.
Molecular Immunology|February 21, 2015
Complement in therapy and disease: Regulating the complement system with antibody-based therapeuticsJoost P M Melis, Kristin Strumane, Sigrid R Ruuls, et al.
ACS Nano|December 31, 2019
Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen RecognitionJürgen Strasser, Rob N de Jong, Frank J Beurskens, et al.
Molecular Immunology|July 16, 2011
Complement activation by (auto-) antibodiesNina A Daha, Nirmal K Banda, Anja Roos, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Molecular Immunology|June 3, 2015
C1q, antibodies and anti-C1q autoantibodiesFrank J Beurskens, Rosanne A van Schaarenburg, Leendert A Trouw
Critical Reviews in Immunology|June 19, 2014
Complement in antibody-based tumor therapyStefanie Derer, Frank J Beurskens, Thies Rosner, et al.
Seminars in Immunology|January 1, 2025
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approachesVitalijs Ovcinnikovs, Karin Dijkman, Gijs G Zom, et al.
Infection and Immunity|December 11, 2019
Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7Srinjoy Chakraborti, Sunita Gulati, Bo Zheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 22, 2024
Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen bindingNikolaus Frischauf, Jürgen Strasser, Ellen G F Borg, et al.
Small Science|July 16, 2025
A Kinetic Model of Antigen-Dependent IgG Oligomerization and Complement BindingJürgen Strasser, Nikolaus Frischauf, Lukas Schustereder, et al.
HLA|May 6, 2026
Blockade of Complement Cell Lysis and C3d Fixation by Patient HLA-A1 Antibodies: Towards a New Therapy for Prevention of Antibody-Mediated RejectionTineke Kardol-Hoefnagel, Dilara Akharman-Oztoprak, Els van der Meijden, et al.
Molecular Immunology|February 21, 2015
Complement in therapy and disease: Regulating the complement system with antibody-based therapeuticsJoost P M Melis, Kristin Strumane, Sigrid R Ruuls, et al.
ACS Nano|December 31, 2019
Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen RecognitionJürgen Strasser, Rob N de Jong, Frank J Beurskens, et al.
Molecular Immunology|July 16, 2011
Complement activation by (auto-) antibodiesNina A Daha, Nirmal K Banda, Anja Roos, et al.
Pageof 5